Activity of group-transported horses during onboard rest stops

Activity of group-transported horses was evaluated during onboard rest stops to determine if horses derive meaningful rest. A single-deck semi-trailer separated into three compartments was used for all shipments. In Experiment One, twelve video cameras were used to record behavior of horses during five, 16 to 20 h shipments, with a high (397.44kg/m2), medium (348.48 kg/m2) and low (220.91 kg/m2) density group in each shipment. One-hour rest stops occurred after 8 h of transport and prior to unloading, during which two groups were provided water. Movement of each horse visible on video was quantified by counting the number of times the head crossed the vertical and/or horizontal axes of the body at the withers. Mean number of movements per 5-min interval in each group (n=13) was used to compare effects of density, access to water, and order of stops. The high and low-density watered groups had increased activity during the first 10 min of both rest stops potentially due to maneuvering for access to water. The medium-density watered groups had increased activity during the first 10 min of only the second rest stop. Activity slightly increased in the medium and low-density groups after 55 min possibly indicating adequate rest, but a similar increase did not occur in highdensity groups. In Experiment Two, two shipments, lasting 23 h and 24 h respectively, consisted of three groups of horses loaded at high density (397.32 kg/m2). Ninety-minute rest stops occurred after every 6 h of transport and prior to unloading for a total of three rest stops. Percentage of visible horses "active" was averaged across each 5-min interval of the stop. Activity was highly variable within and between shipments. Activity was high at the beginning of stops one and three of Shipment One. A similar but less dramatic settling occurred at the start of all three rest stops in Shipment Two. Twenty three of thirty-four noted increases in alertness were due to aggression or noises outside the trailer. In both experiments horses remained active during all stops indicating fatigue had not become a major factor in these studies

Effectiveness of a Perceived Solid Barrier as an Exclusion Fence to Prevent White-Tailed Deer Damage

We hypothesized that a visually solid barrier of cloth would provide an effective exclusion fence for free ranging white-tailed deer (Odocoileus virginianus). Three plots consisting of 2, 10 m x 10 m squares were established in pastures. Data were collected daily for consumption of com provided (2.27 kg) and events recorded by infrared game monitors. Following construction of the burlap fence at 1.7 m height, corn consumption decreased (0.07 ± 0.01 kg/day, P \u3c .001). The number of Infrared monitor events recorded also decreased within the enclosures (2.13 ± 0.04 events/day, P \u3c .001) compared to controls (46.0 ± 2.2 events/day). During the second stage of the experiment, two of the three plots were reestablished 45 days later. Fence heights began at 65 cm and were raised 15 cm each 5 days, until reaching 1.7 m. At 1.7 m, corn consumption decreased by 30% (1.56 ± 0.23 kg/day, P \u3c .01). The number of infrared monitor-recorded events was also lower at fence heights \u3e65 cm (P \u3c .03). Results indicate that a visually solid barrier has potential to be an effective exclusion fence

Effectiveness of a White-Tailed Deer Exclusion Fence Based on Traction Limitations of the Hoof: The Slipper Fence

We hypothesized that an exclusion fence could be devised to capitalize on traction limitations of the hooves of white-tailed deer (Odocoileus virginianus). Hexagonal plots (9.8 m wide) enclosed by a 2.4 m field fence with two openings (4.9 m) were established. Data were collected daily on consumption of corn provided (2.27 kg) and events recorded by infrared monitors (IR) for treatment and control sites. Five-day treatment periods consisted of test panels (4.9 m x 2.4 m) placed in plot openings at 0°, 5° and 10° slopes, and lubricant applied at the 10° slope. Deer consumed all corn provided at control sites. At the 10 ° slope, daily corn consumption decreased (1.50 kg ± 0 .26, p \u3c .0 l ), and IR events were lower (p \u3c .01) at treatment sites (23.6 ± 3.2) compared to controls (50.3 ± 9.6). With the addition of a lubricant, corn consumption decreased further (p \u3c .001) to 0. 17 kg ± 0.03, and IR recorded events were lower (p \u3c .001) at treatment sites (6.58 ± 0 .89) compared to controls (44.8 ± 3.1). Results of this study indicate that traction limitation of the hoof can be exploited

The Potential of Texture as a Deer Deterrent: The Slime Effect

We examined the potential of altering the surface texture of plant material as a potential deterrent to consumption by white-tailed deer. Two u-shaped garden plots were divided into 16, uniform plots (2.2mx4.3m) each containing approximately 50 chrysanthemums (C. morifolium). The plots were randomly assigned to one of the treatments or as a control. Immediately after planting, ten plants were randomly selected and marked within each plot. Plants were misted and treatments applied by hand broadcast. Treatments consisted of methyl cellulose (38.2g) and two-levels of a proprietary polymer (9. lg and 45.5g). Upon contact with water, methyl cellulose became a viscous slime while the proprietary polymer was similar to gelatin. Each substance was visible on the plants throughout the study. Bite marks were counted on the ten marked plants within each plot, on 4 occasions at 3-day intervals. None of the treatments were effective in deterring deer from consuming plant material. Differences were noted among plot locations, suggesting deer entered the garden predominantly from a single general direction and consumed forages most readily available

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Validation of a novel cognitive bias task based on difference in quantity of reinforcement for assessing environmental enrichment

Abstract Cognitive bias tasks purport to assess affective states via responses to ambiguous stimuli. We hypothesized that a novel cognitive bias task based on positive reinforcement using quantity differences would detect changes in affect in captive grizzly bears (Ursus arctos horribilis). We trained bears (n = 8) to respond differently (nose or paw touch) to two stimuli (light or dark gray cue cards), with responses counterbalanced across bears. The two cues signaled a small or large food reward, respectively. Responses to ambiguous probe stimuli (i.e., shades of gray) intermediate to the trained stimuli were classified as either 'optimistic,' appropriate for the larger reward, or 'pessimistic,' appropriate for the smaller reward. In Experiment 1, we explored the contrast in reward size necessary to detect a change in response across probe stimuli (large reward, 3 or 6 apple slices: small reward, 1 slice). We observed a change in response across probe stimuli, with no difference in response between rewardvalue groups, indicating that a contrast of 3:1 apple slices was sufficient to affect responses. In Experiment 2, we investigated cognitive bias after 2.1 h of exposure to enrichment items varying in attractiveness. Results were unaffected by enrichment type or time spent interacting with enrichments, indicating that the task failed to demonstrate criterion validity for comparing mood following exposure to different enrichment items. However, greater time spent pacing prior to testing was associated with 'optimistic' judgments. The data provide some support for use of cognitive bias tasks based on quantity differences in animal welfare assessments involving captive wildlife

Two to five repeated measurements per patient reduced the required sample size considerably in a randomized clinical trial for patients with inflammatory rheumatic diseases

<p>Abstract</p> <p>Background</p> <p>Patient reported outcomes are accepted as important outcome measures in rheumatology. The fluctuating symptoms in patients with rheumatic diseases have serious implications for sample size in clinical trials. We estimated the effects of measuring the outcome 1-5 times on the sample size required in a two-armed trial.</p> <p>Findings</p> <p>In a randomized controlled trial that evaluated the effects of a mindfulness-based group intervention for patients with inflammatory arthritis (n=71), the outcome variables Numerical Rating Scales (NRS) (pain, fatigue, disease activity, self-care ability, and emotional wellbeing) and General Health Questionnaire (GHQ-20) were measured five times before and after the intervention. For each variable we calculated the necessary sample sizes for obtaining 80% power (α=.05) for one up to five measurements.</p> <p>Two, three, and four measures reduced the required sample sizes by 15%, 21%, and 24%, respectively. With three (and five) measures, the required sample size per group was reduced from 56 to 39 (32) for the GHQ-20, from 71 to 60 (55) for pain, 96 to 71 (73) for fatigue, 57 to 51 (48) for disease activity, 59 to 44 (45) for self-care, and 47 to 37 (33) for emotional wellbeing.</p> <p>Conclusions</p> <p>Measuring the outcomes five times rather than once reduced the necessary sample size by an average of 27%. When planning a study, researchers should carefully compare the advantages and disadvantages of increasing sample size versus employing three to five repeated measurements in order to obtain the required statistical power.</p